COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib

被引:0
|
作者
Emma Bell
Frida Ponthan
Claire Whitworth
Deborah A. Tweddle
John Lunec
Christopher P. F. Redfern
机构
[1] Newcastle University,Northern Institute for Cancer Research
[2] German Cancer Center,Division of Neuroblastoma Genomics (B087)
来源
关键词
Neuroblastoma; Cyclooxygenase; COX2; Arachidonic acid; Celecoxib;
D O I
暂无
中图分类号
学科分类号
摘要
COX2 is an inducible cyclooxygenase implicated in the metastasis and migration of tumour cells. In neuroblastoma, COX2 expression has been detected in both cell lines and tumours. The treatment of neuroblastoma cells in vitro with celecoxib, a COX2 inhibitor, induces apoptosis. The aim of this study was to investigate the role of COX2 in neuroblastoma tumour biology by creating a cell line in which COX2 could be conditionally expressed. Xenograft studies showed that the conditional expression of COX2 enhanced tumour growth and malignancy. Elevated COX2 expression enhanced the proliferation and migration of neuroblastoma cells in vitro. However, elevated COX2 expression or variation between cell lines did not affect sensitivity to the COX2 inhibitor celecoxib, indicating that celecoxib does not promote cell death through COX2 inhibition. These data show that increased COX2 expression alone can enhance the tumorigenic properties of neuroblastoma cells; however, high levels of COX2 may not be a valid biomarker of sensitivity to non-steroidal anti-inflammatory drugs such as celecoxib.
引用
收藏
页码:651 / 659
页数:8
相关论文
共 50 条
  • [1] COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib
    Bell, Emma
    Ponthan, Frida
    Whitworth, Claire
    Tweddle, Deborah A.
    Lunec, John
    Redfern, Christopher P. F.
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2014, 31 (06) : 651 - 659
  • [2] Tumor COX2 expression does not affect colorectal cancer survival
    Rebecca Doherty
    [J]. Nature Clinical Practice Oncology, 2005, 2 (10): : 485 - 485
  • [3] Prevalence of COX2 expression in Middle Eastern CRC and the effect of COX2 inhibitors on cell growth in the mouse model of CRC
    Ahmed, Maqbool
    Bavi, Prashant
    Hussain, Azhar
    Al-Sanea, Nasser
    Abduljabbar, Alaa
    Ashari, Luai
    Alhomoud, Samar
    Al-Dayel, Fouad
    Uddin, Shahab
    Al-Kuraya, Khawla
    [J]. CANCER RESEARCH, 2009, 69
  • [4] COX2 gets complex
    不详
    [J]. NATURE MEDICINE, 2004, 10 (11) : 1172 - 1172
  • [5] Expression of COX2 in uterine serous carcinoma
    Nassar, H
    Arabi, MH
    Bandyopdhyay, S
    Munkarah, A
    Ali-Fehmi, R
    [J]. LABORATORY INVESTIGATION, 2005, 85 : 197A - 197A
  • [6] Expression of COX2 in uterine serous carcinoma
    Nassar, H
    Arabi, MH
    Bandyopdhyay, S
    Munkarah, A
    Ali-Fehmi, R
    [J]. MODERN PATHOLOGY, 2005, 18 : 197A - 197A
  • [7] Future of COX2 inhibitors
    Melnikova, I
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (06) : 453 - 454
  • [8] The development of COX2 inhibitors
    Rod J. Flower
    [J]. Nature Reviews Drug Discovery, 2003, 2 : 179 - 191
  • [9] The development of COX2 inhibitors
    Flower, RJ
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (03) : 179 - 191
  • [10] Effect of NOS inhibitor on cytokine and COX2 expression in rat pulpitis
    Kawashima, N
    Kawanishi, HN
    Suzuki, N
    Takagi, M
    Suda, H
    [J]. JOURNAL OF DENTAL RESEARCH, 2005, 84 (08) : 762 - 767